<DOC>
	<DOCNO>NCT00744302</DOCNO>
	<brief_summary>A prospective , randomize , control multicenter trial evaluate 1.25 mmol/L ( physiological ) vs. 1.5 mmol/L calcium dialysate serum marker mineral metabolism , secondary hyperparathyroidism cardiovascular calcification prevalent haemodialysis patient . And long term safety 1.25 mmol/L calcium dialysate also consider . There two phase study subject . Phase 1 ( screen phase ) . During phase , potential subject evaluate determine he/she eligible study . Phase 2 ( intervention phase ) . Each subject randomly allocate physiological calcium dialysate ( 1.25 mmol/L calcium dialysate ) group ( PCD group ) , normal calcium dialysate ( 1.5 mmol/L calcium dialysate ) group ( NCD group ) . The follow-up duration 36 month .</brief_summary>
	<brief_title>Study 1.25 mmol/L Calcium Dialysate Mineral Metabolism Haemodialysis Patients .</brief_title>
	<detailed_description>All patient recruit center meet inclusion criterion randomly allocate physiological calcium dialysate ( 1.25 mmol/L calcium dialysate ) group ( PCD group ) , normal calcium dialysate ( 1.5 mmol/L calcium dialysate ) group ( NCD group ) . The follow-up duration 36 month . Calcium carbonate mainly use phosphate binder . Active vitamin D metabolite , calcitriol ( Rocaltrol , Hoffmann La Roche , Basel , Switzerland ) give control secondary hyperparathyroidism . The dos agent adjust accord serum calcium level , serum phosphate level , calcium-phosphorus product serum iPTH level , recommend K/DOQI Guidelines 6.3b 8B . Aluminum hydroxide might introduce phosphate binder 4 week addition calcium carbonate dietary restriction serum phosphate level could get good control ( serum P level≥1.78 mmol/L , last 4 week ) . A non- calcium-containing phosphate binder could administer 1~2 week patient hypercalcaemia observation . At time study , non-calcium , non-aluminum base phosphate binder well calcium acetate available country .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Willingness sign inform consent Stable haemodialysis treatment 3 month , undergo 2 3 time haemodialysis week 4 5 hour per session Secondary hyperparathyroidism define serum intact parathyroid hormone ( iPTH ) &gt; 150 pg/mL , hypercalcemia define serum Ca &gt; 2.2 mmol/L /or calcium phosphate product ≥55mg2/dl2 Inability unwillingness sign inform consent Cardiac arrhythmia Serious renal osteopathy Oral active vitamin D and/or calcium carbonate intolerance Poor compliance unwillingness meet scheme demand raise investigator Patients undergone percutaneous ethanol injection therapy parathyroidectomy secondary hyperparathyroidism Patients previously treat and/or treat glucocorticoid , affect bone metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Dialysate calcium</keyword>
	<keyword>Mineral metabolism</keyword>
	<keyword>Parathyroid hormone</keyword>
	<keyword>Calcification</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Haemodialysis</keyword>
</DOC>